中国生物制药上半年收入175.75亿元 增长10.7%

Group 1 - The core point of the article highlights that China Biopharmaceutical reported a significant increase in its financial performance for the first half of 2025, with a notable rise in both revenue and profit [3] - The company's revenue for the six months ending June 30, 2025, was approximately RMB 17.575 billion, reflecting a year-on-year growth of 10.7% [3] - The profit attributable to the parent company holders from continuing operations was around RMB 3.389 billion, showing a substantial year-on-year increase of 140.2% [3] - Basic earnings per share were approximately RMB 0.1882, which represents a year-on-year growth of 145.7% [3] - The profit growth was primarily driven by significant revenue increases, as well as gains from dividend income and changes in the fair value of investments [3] Group 2 - After adjustments, the basic profit attributable to the parent company holders was approximately RMB 3.088 billion, marking a substantial year-on-year increase of 101.1% [1] - The board of directors announced an interim dividend of HKD 0.05 per share [1]